Nile Therapeutics appoints Darlene Horton as CMO

Friday, June 22, 2012 10:19 AM

Nile Therapeutics, a San Mateo, Calif.-based biopharmaceutical company that develops novel therapeutics for heart failure patients, has appointed Darlene Horton, M.D. as its chief medical officer.

Horton was previously served as CMO of Itero Biopharmaceuticals, a venture-backed company that developed and out-licensed a biosimilar protein therapeutic. Prio to Itero, she served as senior vice president of clinical research at Scios, a Johnson & Johnson company. During Horton’s 12 year tenure at Scios, she was the clinical lead for Natrecor, a commercial product indicated for the treatment of acute heart failure. Following the acquisition of Scios by J&J, Horton also served as the head of the Cardiovascular Therapeutic Area Center of Excellence for all of J&J pharmaceutical companies.

Share:          
CWWeekly

July 6

FDA sued by advocacy groups seeking hepatitis C trials data

Google to test health-tracking wristband to collect clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs